| Popis: |
Predicting the future in almost any realm of human endeavor is a challenging and humbling undertaking, given the large number of variables often at play, uncertainty as to how known variables impact each other, the frequent presence of significant but largely unrecognized variables, and the even more daunting task of estimating timing in the unfolding of future changes. With the identification of human papilloma virus (HPV) as the dominant etiologic agent of cervical cancer,[1,2] the introduction of FDA-approved adjunctive HPV DNA testing with cytology as early forms of etiology-based screening[3,4] and the recent introduction of FDA-approved vaccination for the two leading high-carcinogenic-risk HPV types,[5] it is perhaps not surprising that recent predictions about the future structure of cervical cancer prevention efforts in the USA and the size and scope of the role of the Papanicolaou test in US cervical cancer screening have varied greatly.[6–13] In an effort to help members assess the future of the Pap test market in the USA, the American Society of Cytopathology (ASC) recently contracted with an external research group FGI Research of Chapel Hill, North Carolina, to survey a diverse group of US Pap test providers on their personal expectations for future Pap testing volume in their practices. Questions to be asked of Pap test providers were initially developed by the ASC Long Range Planning Committee and subsequently edited by the ASC Executive Board and FGI Research. Along with the specific questions asked, the Survey findings are presented here for further consideration by the ASC membership [see PDF of FGI PowerPoint presentation - Report of findings - http://www.cytojournal.com/articles/2009/6/1/images/CytoJournal_2009_6_1_17_55885_sm1.pdf]. |
